“Lilly scientists delivered the first doses of our potential #COVID19 antibody treatment, flown to hospitals in several U.S. cities to start the world’s first human study of this kind of therapy to fight COVID infections.” @lillypad

• First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly’s collaboration with AbCellera
• The placebo-controlled study will assess safety and tolerability in patients hospitalized with COVID-19 with results anticipated by the end of June
• Should Phase 1 results show the antibody can be safely administered, Lilly will initiate a Phase 2 proof of concept study to assess efficacy in vulnerable populationsContinue reading→

Findings on compounds that block SARS-COV-2 viral replication may offer a promising starting point for further development of treatments to address the ongoing, devastating novel coronavirus pandemic.Continue reading→

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. Today’s announcements are:

• Merck to acquire Themis Bioscience, a company focused on vaccines and immune-modulation therapies for infectious diseases, including COVID-19;
• IAVI and Merck collaborate to develop vaccine against COVID-19;
• Merck and Ridgeback Bio collaborate to advance development of an oral antiviral candidate for COVID-19, EIDD-2801.

Continue reading→

University of Arizona President Dr. Robert C. Robbins announced in April his plans to resume in-person classes Aug. 24, bringing back 45,000 students and 15,000 faculty and staff for fall 2020.Continue reading→

Practiced together, CDC guidelines help to reduce riskContinue reading→

The project will leverage an existing online survey tool that researchers have used to investigate risk factors for Alzheimer’s disease.

Continue reading→

The United States Patent and Trademark Office (USPTO) has introduced a pilot program to provide prioritized patent examination for patent applications that cover a product or process related to COVID-19. The product or process must be subject to an applicable U.S. Food and Drug Administration (FDA) approval for COVID-19 use.Continue reading→

Tucson, Ariz. – The University of Arizona and state of Arizona antibody testing initiative will include 31 sites across the state as it expands to all 15 counties.Continue reading→

Sarah Arrowsmith, lab coordinator and scientist at Biodesign Institute Center for Environmental Biotechnology, stepped up to make coth masks for others.  The team at the ASU Biodesign institute ran tests to determine how effective these homemade masks may be. Continue reading→